Protocol T study
RETINA
This post hoc analysis utilises data from the DRCR Retina Network Protocol T trial (NCT01627249). The study was chosen as it was a large, well-designed trial for which data were available [A detailed description of the methodology, participants, and outcomes has been published [Starting at the 24-week visit, irrespective of VA and CST, an injection was withheld if there was no improvement or worsening on both VA and CST measurements after two consecutive injections, but reinitiated if the VA letter score or CST worsened due to DMO. This strict retreatment protocol allowed flexible individualised treatment, as needed, to maximise gains in BCVA for all participants. During the first year, follow-up visits occurred every 4 weeks (±1 week). During the second year, visits were every 4–16 weeks, depending on treatment course.The prespecified primary outcome measures were change in VA, assessed by electronic ETDRS letter scores, from baseline to 12 months/24 months in the overall population and cohorts of participants with a baseline VA letter score of 78‒69 (between 20/32 and 20/40) or <69 (20/40 or worse).